ClinicalTrials.gg

Program

treprostinil hexadecyl ester

Also written as “Treprostinil Palmitil Inhalation Powder”, “Treprostinil Palmitil” and “TPIP F2”.

Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Lung Diseases, Interstitial, led by Insmed.

Furthest: phase 3, since Dec 6, 202212 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Insmed126 open or runningphase 3since Dec 6, 2022Mar 8, 2021Dec 31, 2026phase 3 · NCT05649748

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2021First study: phase 2 study in Pulmonary Arterial HypertensionFirst studyNCT04791514 · 1 enrolled · United States
  2. Nov 24, 2021Phase 2 study in Pulmonary Arterial HypertensionNCT05147805 · 102 enrolled · United States, Argentina, Australia and more
  3. Dec 10, 2021Phase 2 study in Hypertension, PulmonaryNCT05176951 · 39 enrolled · Argentina, Australia, Belgium and more
  4. Dec 6, 20222 phase 3 studiesNCT05649748, NCT05649722
  5. Oct 16, 2023Phase 1 study in Healthy VolunteersNCT06091579 · 42 enrolled · United States
  6. Jul 28, 2025Phase 1 study in Healthy VolunteersNCT07102316 · 42 enrolled · United States
  7. Sep 10, 2025Phase 3 study in Hypertension, PulmonaryNCT07179380 · 344 planned · United States, Argentina, Australia and more
  8. Nov 14, 2025Phase 3 study in Hypertension, PulmonaryNCT07234032 · 344 planned · United States, Czechia, France and more
  9. Mar 13, 2026Phase 3 study in Pulmonary Arterial HypertensionNCT07481981 · 344 planned · United States, Argentina, Australia and more
  10. Jun 8, 2026Phase 1 study in Hepatic ImpairmentNCT07643155 · 30 planned · United States
  11. Sep 1, 2026Phase 3 study in Lung Diseases, InterstitialNCT07805785 · 800 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Pulmonary Arterial HypertensionNCT05649748
  2. Feb 7, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07643155
  3. Dec 28, 2028Primary completion: phase 3 study in Pulmonary Arterial HypertensionNCT07481981
  4. Dec 30, 2028Primary completion: phase 3 study in Hypertension, PulmonaryNCT07179380

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07805785Lung Diseases, Interstitial · United States3RecruitingAug 31, 2030800
NCT07643155Hepatic Impairment · United States1RecruitingFeb 7, 202730
NCT07481981Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3RecruitingDec 28, 2028344
NCT07234032Hypertension, Pulmonary · United States, Czechia, France and more3RecruitingJan 22, 2031344
NCT07179380Hypertension, Pulmonary · United States, Argentina, Australia and more3RecruitingDec 30, 2028344
NCT07102316Healthy Volunteers · United States1CompletedOct 25, 202542
NCT06091579Healthy Volunteers · United States1CompletedJan 12, 202142
NCT05649748Pulmonary Arterial Hypertension · United States, Argentina, Austria and more3Active, not recruitingDec 31, 202691
NCT05649722Hypertension, Pulmonary · Argentina, Australia, Belgium and more3CompletedApr 1, 202631
NCT05176951Hypertension, Pulmonary · Argentina, Australia, Belgium and more2CompletedMar 14, 202439
NCT05147805Pulmonary Arterial Hypertension · United States, Argentina, Australia and more2CompletedMar 27, 2025102
NCT04791514Pulmonary Arterial Hypertension · United States2TerminatedAug 26, 20221

How it is read

Names in the registry

  • “Treprostinil Palmitil Inhalation Powder”, 7 entries
  • “Treprostinil Palmitil”, 4 entries
  • “TPIP F2”, 1 entry
  • “TPIP F3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
treprostinil hexadecyl ester (Insmed): development program | ClinicalTrials.gg